![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Two Years of Truvada for Pre-Exposure Prophylaxis
Utilization in the United States
|
|
|
Reported by Jules Levin
HIV Drug Therapy
November 2-6, 2014
Glasgow, UK
C Flash1, R Landovitz2, R Mera-Giler3, L Ng3, D Magnuson3, S Bush-Wooley4, K Rawlings4
1Baylor College of Medicine, Medicine, Section of Infectious Diseases, Houston, United States;
2David Geffen School of Medicine, Medicine, Division of Infectious Diseases, Los Angeles, United States;
3Gilead Sciences, Drug Safety & Public Health, Foster City, United States;
4Gilead Sciences, Medical Affairs, Foster City, United States
![Glascow1.gif](../images/110714/110714-6/Glascow1.gif)
![Glascow2.gif](../images/110714/110714-6/Glascow2.gif)
![Glascow3.gif](../images/110714/110714-6/Glascow3.gif)
![Glascow4.gif](../images/110714/110714-6/Glascow4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|